home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    UK PHARMA PATENTS UP 20%, NEW REPORT FINDS

    Mar 20, 2019

    The pharma industry saw double-digit growth in patent filings for the second year in a row in 2018, with applications from the UK up by a fifth, according to the latest data released by the European Patent Office (EPO). There were 7,441 filings in the pharmaceutical category throughout 2018, up from...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28232823

    QUESTION MARKS OVER ABBVIE/ROCHE’S VENETOCLAX AFTER SAFETY SCARE

    Mar 20, 2019

    AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths were observed in patients receiving it than in a trial’s control arm. AbbVie, which is developing the drug in partnership with Roche, said the par...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28242824

    DAILY ASPIRIN NO LONGER RECOMMENDED BY DOCTORS

    Mar 20, 2019

    NEW YORK: For years, low-dose aspirin has been described as a panacea to ward off heart attacks, strokes and another cardiovascular disease. New guidelines, though, suggest that aspirin should not be prescribed to most adults who are in good cardiovascular health and that the risk of internal bleedi...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28252825

    ALEXION INKS TWO PARTNERSHIPS: AFFIBODY AB AND ZEALAND PHARMA

    Mar 20, 2019

    Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases. ABY-039 is currently in Phase I dev...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28262826

    WILL GSK/TESARO’S CHECKPOINT INHIBITOR BE ABLE TO COMPETE WITH MERCK’S KEYTRUDA?

    Mar 20, 2019

    Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer. An anti-PD-1 antibody checkpoint inhibitor, many are looking to dostarlimab as being a potential competitor with Merck&r...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28272827

    FRANCE’S DOCTOLIB IS NEW DIGITAL HEALTH UNICORN

    Mar 20, 2019

    Doctolib, the largest digital health service in Europe, has raised 150 million euros in a funding round, valuing it at over a billion euros. Thanks to the funding round led by growth equity firm General Atlantic, France’s Doctolib has become a privately-owned digital health “unicorn&rdqu...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28282828

    SEVEN FUTURE BLOCKBUSTER DRUGS TO LOOK OUT FOR IN 2019

    Mar 20, 2019

    AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023. JAK1 inhibitor upadacitinib for rheumatoid arthritis will be a $2.2 billion product by that time, predicts Clarivate Analytics, desp...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28292829

    MORE OVARIAN CANCER WOES FOR MERCK KGAA AND PFIZER AS THEY HALT LATE-STAGE TRIAL

    Mar 20, 2019

    Merck KGaA, Darmstadt, Germany, and Pfizer discontinued a Phase III ovarian cancer drug trial after determining that the degree of benefit observed in the treatment during an interim analysis does not support the continuation of the trial. It was the second ovarian cancer trial the two companies col...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=28302830

TRENDING NEWS


    IBM IS ENDING SALES OF WATSON FOR DRUG DISCOVERY

    Apr 19, 2019

    IBM is stopping development and sales of its tool that utilizes Watson AI to help pharmaceutical companies find new drugs, according to a STAT report. A source told STAT that the product, Watson for Drug Discovery, wasn’t yielding large enough financial returns. The source noted that some IBM ...


    READ MORE

    https://medcitynews.com/2019/04/report-ibm-watson-for-drug-discovery/2964

    MASS TORT ALLEGES GILEAD SCIENCES, INC. WITHHELD SAFER DRUGS FROM HIV/AIDS PATIENTS, MANIPULATED PATENT TIMING FOR PROFIT, ANNOUNCES JENNER LAW

    Apr 19, 2019

    Eight patients who took the popular HIV/AIDS drug Truvada and similar tenofovir-based drugs have sued Gilead Sciences, Inc., claiming the giant pharmaceutical company deliberately withheld a much safer version of these drugs from the market for more than a decade in a patent-timing scheme to maximiz...


    READ MORE

    https://www.prnewswire.com/news-releases/mass-tort-alleges-gilead-sciences-inc-withheld-safer-drugs-from-hivaids-patients-manipulated-patent-timing-fo2965

    THE FDA JUST APPROVED THE FIRST GENERIC NASAL SPRAY TO REVERSE OPIOID OVERDOSES

    Apr 19, 2019

    The Food and Drug Administration (FDA) on Friday announced that it granted final approval to the first generic naloxone hydrochloride nasal spray, which can be used to reverse opioid overdoses. The approval is part of the FDA’s wider effort to make tools for stopping or preventing opioid overd...


    READ MORE

    http://time.com/5574107/fda-generic-naloxone-nasal-spray/2966

    THE SUPERBUG IS RISING: WHERE ARE THE NEW ANTIBIOTICS?

    Apr 19, 2019

    According to Alan Westwood, chief executive of Matoke, a company hoping to develop a new form of antibiotic, the issue of antibiotic resistance is one of the most troubling issues of our times. It is one of the biggest threats to human health. In 30 years, it’s estimated 10 million people will...


    READ MORE

    https://gulfnews.com/world/americas/the-superbug-is-rising-where-are-the-new-antibiotics-1.633488702967

    DRUGMAKERS REVEAL LIST PRICES ONLINE AFTER PRESSURE FROM TRUMP

    Apr 19, 2019

    The world's biggest pharmaceutical companies are revealing prices of their prescription drugs on websites for the first time in a bid to stave off pressure from the Trump administration to make even more public disclosures. The move by companies ranging from pharma giant Pfizer to biotechnology ...


    READ MORE

    https://www.houstonchronicle.com/news/article/Drugmakers-reveal-list-prices-online-after-13780612.php2968

    PFIZER AND LILLY'S NON-OPIOID PAINKILLER SHOWS MIXED RESULTS IN PHASE III

    Apr 19, 2019

    Pfizer and Eli Lilly and Company announced top-line results from a Phase III clinical trial of two doses of tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee. The results were mixed, with the 5 mg dose meeting two of the three co-primary efficacy endpoints but missing on the pat...


    READ MORE

    https://www.biospace.com/article/pfizer-and-eli-llly-s-tanezumab-has-mixed-results-in-osteoarthritis-trial/2969

    DISPENSED: INTRODUCING BUSINESS INSIDER'S 10 PEOPLE TRANSFORMING HEALTHCARE

    Apr 19, 2019

    Welcome to another dose of Dispensed, Business Insider's weekly healthcare newsletter! Before heading out for the holiday weekend, I wanted to highlight some of the great work the healthcare team here has been pulling together. The entire Business Insider newsroom got together to compile a list ...


    READ MORE

    https://www.businessinsider.in/Dispensed-Introducing-Business-Insiders-10-people-transforming-healthcare/articleshow/68957803.cms2970

    POT STOCKS SOARING, CANNABIS INDUSTRY POISED FOR 'TONS OF GROWTH'

    Apr 19, 2019

    (CNN) - For decades, though nobody was really sure why, April 20 has been the unofficial holiday for marijuana users and a joke by and about them. Now, though, it's also a reminder of how quickly marijuana is moving from illegal and a joke to a multi-billion-dollar legal business and a good time...


    READ MORE

    https://www.koamnewsnow.com/news/money/pot-stocks-soaring-cannabis-industry-poised-for-tons-of-growth/10706308992971

    NICE BACKS AKCEA’S TEGSEDI, PIPPING ALNYLAM TO HATTR OKAY

    Apr 18, 2019

    NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam. Both Tegsedi (inotersen) and Alnylam’s rival hATTR therapy Onpattro (patisiran) were turned down by the...


    READ MORE

    https://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/2962

    ANTIBODY SUPPRESSES HIV FOR FOUR MONTHS

    Apr 18, 2019

    A new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the virus for up to four months after patients stopped taking antiretroviral medicines. Developed by Taiwan’s United Bio Pharma and one of the US government-funded National Institutes of Health...


    READ MORE

    https://pharmaphorum.com/news/antibody-suppresses-hiv-for-four-months/2963

    HI-TECH RESPONDS TO "BULLYING TACTICS" ISSUED BY FDA WARNING LETTER ON DMHA

    Apr 17, 2019

    Hi-Tech Pharmaceuticals once again states that FDA's attempt to quasi ban a product by warning letter rather than rulemaking is not the law. Hi-Tech is working on a response to the agency but wanted consumers to know Hi-Tech will not just roll over due to an ill informed warning letter. Hi-Tech ...

    HI-TECH PHARMACEUTICALS, INC.
    READ MORE

    https://www.biospace.com/article/releases/hi-tech-responds-to-and-quot-bullying-tactics-and-quot-issued-by-fda-warning-letter-on-dmha/2951

    SCIENTISTS ENTER RESEARCH COLLABORATION TO OUTSMART CANCER

    Apr 17, 2019

    Cancer is a disease that afflicts an alarming number of people, with one in two being diagnosed with a type of cancer during their lifetime. The global cancer burden has risen to 18.1 million people in 2018, which makes cancer one of the leading causes of death worldwide. While clinical developments...

    EUREKALERT
    READ MORE

    https://www.eurekalert.org/pub_releases/2019-04/imi-ser041719.php2952

    TURNING POINT PRICES IPO, RAISING $166M TO TEST CANCER DRUGS

    Apr 17, 2019

    Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. Strong demand ahead of the offering prompted the company, which is developing targeted cancer drugs for...

    XCONOMY
    READ MORE

    https://xconomy.com/san-diego/2019/04/17/turning-point-prices-ipo-raising-166m-to-test-cancer-drugs/2953

    FSD PHARMA TO PRESENT AT ARCVIEW INVESTOR FORUM

    Apr 17, 2019

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that Dr. Raza Bokhari, Co-Chairman and Chief Executive Officer of FSD Pharma will participate in the Arcview Investor Forum being held April 23-25, 2019, in Vancouver. The event will f...

    SD PHARMA INC.
    READ MORE

    https://www.biospace.com/article/releases/fsd-pharma-to-present-at-arcview-investor-forum/2954

    QUARTESIAN LLC EXECUTES MULTI-YEAR ENTERPRISE AGREEMENT WITH MEDRIO, SECURING ACCESS TO INNOVATIVE ECLINICAL FUNCTIONALITY AND SUPPORT SERVICES

    Apr 17, 2019

    Quartesian LLC, a full-service contract research organization (CRO) providing data management, biostatistics, and other services to clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading provider of eClinical technology for clinical trials. The agreement will enable ...

    PRWEB
    READ MORE

    https://www.prweb.com/releases/quartesian_llc_executes_multi_year_enterprise_agreement_with_medrio_securing_access_to_innovative_eclinical_functionali2955

    HEALTHCARE COMPANIES SEARCH FOR NEW WAYS TO OPPOSE THE SPREAD OF CANCER

    Apr 17, 2019

    Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the World Cancer Research Fund (WCRF) estimated that there were 18 million new cancer cases worldwide. ...

    PTCOMMUNITY
    READ MORE

    https://www.ptcommunity.com/wire/healthcare-companies-search-new-ways-oppose-spread-cancer2956

SPOTLIGHT

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high-value decisions through superior quality, timely, must-have data and insi

RESOURCES

Events